Total Payments
$248,259
2024 Payments
$40,930
Companies
26
Transactions
344
Medicare Patients
17,416
Medicare Billing
$8.9M
Payment Breakdown by Category
Consulting$120,502 (48.5%)
Other$70,995 (28.6%)
Research$40,056 (16.1%)
Food & Beverage$11,212 (4.5%)
Travel$5,491 (2.2%)
Education$3.85 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $120,502 | 53 | 48.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,171 | 15 | 17.8% |
| Unspecified | $40,056 | 21 | 16.1% |
| Honoraria | $15,400 | 8 | 6.2% |
| Food and Beverage | $11,212 | 221 | 4.5% |
| Acquisitions | $6,652 | 1 | 2.7% |
| Travel and Lodging | $5,491 | 18 | 2.2% |
| Current or prospective ownership or investment interest | $4,772 | 6 | 1.9% |
| Education | $3.85 | 1 | 0.0% |
Payments by Type
General
$208,203
323 transactions
Research
$40,056
14 transactions
Ownership
$0
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $63,601 | 78 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $36,870 | 27 | $0 (2022) |
| Spark Therapeutics, Inc. | $28,780 | 18 | $0 (2022) |
| Alimera Sciences, Inc. | $28,742 | 37 | $0 (2024) |
| Astellas Pharma US Inc | $26,777 | 23 | $0 (2024) |
| Genentech USA, Inc. | $14,288 | 32 | $0 (2024) |
| US Retina LLC | $12,824 | 16 | $0 (2023) |
| Apellis Pharmaceuticals, Inc. | $10,604 | 18 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $6,003 | 9 | $0 (2024) |
| Novartis Pharma AG | $3,964 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,930 | 71 | Regeneron Healthcare Solutions, Inc. ($19,163) |
| 2023 | $55,682 | 62 | Astellas Pharma US Inc ($26,292) |
| 2022 | $32,471 | 41 | Regeneron Healthcare Solutions, Inc. ($13,893) |
| 2021 | $32,531 | 43 | Novartis Pharmaceuticals Corporation ($8,390) |
| 2020 | $34,254 | 23 | Spark Therapeutics, Inc. ($15,024) |
| 2019 | $35,156 | 42 | Novartis Pharmaceuticals Corporation ($17,179) |
| 2018 | $11,071 | 39 | Spark Therapeutics, Inc. ($3,675) |
| 2017 | $6,164 | 23 | Regeneron Healthcare Solutions, Inc. ($5,277) |
All Payment Transactions
344 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug), Ryzumvi | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: Dry eyes | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $135.01 | General |
| Category: Ophthalmology | ||||||
| 12/10/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $33.68 | General |
| Category: Ophthalmology | ||||||
| 11/11/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $157.25 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $37.51 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/29/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,865.00 | General |
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $552.50 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/20/2024 | Harrow Eye, LLC | IHEEZO (Drug), TRIESENCE | Food and Beverage | In-kind items and services | $77.44 | General |
| Category: OPTOMETRY | ||||||
| 10/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $33.50 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/20/2024 | Harrow Eye, LLC | IHEEZO (Drug), TRIESENCE | Food and Beverage | In-kind items and services | $29.29 | General |
| Category: OPTOMETRY | ||||||
| 10/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $109.13 | General |
| Category: Ophthalmology | ||||||
| 10/18/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $44.93 | General |
| Category: Ophthalmology | ||||||
| 10/03/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $126.95 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 10/03/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $20.58 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 10/02/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Ophthalmology | ||||||
| 09/15/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $1,872.65 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 09/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $49.66 | General |
| Category: Ophthalmology | ||||||
| 09/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,105.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $828.75 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/29/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $29.79 | General |
| Category: Ophthalmology | ||||||
| 08/28/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA, LOTEMAX | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Ophthalmology | ||||||
| 08/27/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $36.81 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/22/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $33.17 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/02/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $4,420.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/02/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $3,315.00 | General |
| Category: OPHTHALMOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Iluvien Study | Alimera Sciences, Inc. | $11,916 | 6 |
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $8,470 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH BEOVU RESEARCH | Novartis Pharmaceuticals Corporation | $8,188 | 2 |
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $7,518 | 2 |
| Publication support research related | Novartis Pharma AG | $3,964 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 4,544 | 35,261 | $3.7M | $2.7M |
| 2022 | 19 | 4,450 | 14,976 | $3.1M | $2.2M |
| 2021 | 18 | 4,556 | 11,597 | $3.0M | $2.3M |
| 2020 | 18 | 3,866 | 8,934 | $2.4M | $1.8M |
Total Patients
17,416
Total Services
70,768
Medicare Billing
$8.9M
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 192 | 1,476 | $1.4M | $994,072 | 72.8% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 73 | 24,720 | $955,576 | $718,019 | 75.1% |
| J3490 | Unclassified drugs | Office | 2023 | 48 | 148 | $338,636 | $253,975 | 75.0% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,034 | 1,601 | $216,617 | $144,232 | 66.6% |
| 67028 | Injection of drug into eye | Office | 2023 | 316 | 1,414 | $263,310 | $138,362 | 52.5% |
| 92134 | Imaging of retina | Office | 2023 | 1,176 | 2,989 | $130,398 | $91,677 | 70.3% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 24 | 750 | $120,000 | $90,271 | 75.2% |
| J3590 | Unclassified biologics | Office | 2023 | 25 | 37 | $102,953 | $76,311 | 74.1% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 15 | 195 | $52,350 | $35,157 | 67.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 239 | 307 | $29,970 | $21,178 | 70.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 169 | 196 | $27,044 | $19,871 | 73.5% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 16 | 16 | $19,512 | $15,393 | 78.9% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 99 | 99 | $15,887 | $10,931 | 68.8% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 599 | 681 | $11,419 | $7,903 | 69.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 55 | 55 | $10,071 | $7,076 | 70.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 67 | 67 | $8,921 | $6,520 | 73.1% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 47 | 105 | $9,566 | $5,780 | 60.4% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 13 | 17 | $6,142 | $4,883 | 79.5% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 213 | 248 | $6,633 | $4,473 | 67.4% |
| 92250 | Photography of the retina | Office | 2023 | 72 | 79 | $3,160 | $2,163 | 68.5% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 33 | 41 | $2,086 | $1,530 | 73.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Facility | 2023 | 19 | 20 | $1,103 | $625.28 | 56.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 224 | 1,848 | $1.7M | $1.3M | 76.5% |
| J3590 | Unclassified biologics | Office | 2022 | 38 | 90 | $209,250 | $161,419 | 77.1% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 1,017 | 1,575 | $213,535 | $139,761 | 65.5% |
About Dr. Mathew Maccumber, MD
Dr. Mathew Maccumber, MD is a Ophthalmology healthcare provider based in Harvey, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1649270224.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mathew Maccumber, MD has received a total of $248,259 in payments from pharmaceutical and medical device companies, with $40,930 received in 2024. These payments were reported across 344 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($120,502).
As a Medicare-enrolled provider, Maccumber has provided services to 17,416 Medicare beneficiaries, totaling 70,768 services with total Medicare billing of $8.9M. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Harvey, IL
- Active Since 07/26/2005
- Last Updated 02/04/2022
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1649270224
Products in Payments
- EYLEA (Biological) $49,615
- BEOVU (Drug) $24,363
- ILUVIEN (Drug) $22,051
- LUXTURNA (Biological) $13,681
- Vabysmo (Drug) $9,244
- EYLEA AFLIBERCEPT INJECTION (Biological) $7,920
- EYLEA HD (Biological) $7,257
- Iluvien (Drug) $5,236
- VABYSMO (Drug) $4,131
- Jetrea (Drug) $3,000
- OZURDEX (Drug) $2,883
- RTH258A (Drug) $2,520
- EYP-1901 (Drug) $1,973
- MIEBO (Drug) $1,500
- Cimerli (Biological) $1,405
- XIPERE (Drug) $1,109
- Lucentis (Biological) $954.35
- Syfovre (Drug) $835.78
- Izervay (Drug) $484.32
- YUTIQ (Drug) $326.29
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Harvey
Kourous Rezaei, Md, MD
Ophthalmology — Payments: $98,698
Ophthalmology $98,698
David Orth, Md, MD
Ophthalmology — Payments: $70,789
Ophthalmology $70,789
Timothy Flood, Md, MD
Ophthalmology — Payments: $57,253
Ophthalmology $57,253
Dr. Vivek Chaturvedi, M.d, M.D
Ophthalmology — Payments: $48,512
Ophthalmology $48,512
Serge Debustros, Md, MD
Ophthalmology — Payments: $34,365
Ophthalmology $34,365
Sohail Hasan, Md, MD
Ophthalmology — Payments: $30,975
Ophthalmology $30,975